CA2612550A1 - Pyroglutamates de creatine et methodes pour leur production et leur utilisation chez des personnes - Google Patents

Pyroglutamates de creatine et methodes pour leur production et leur utilisation chez des personnes Download PDF

Info

Publication number: CA2612550A1
Authority: CA; Canada
Prior art keywords: creatine; pyroglutamic acid; acid salts; pyroglutamate; individuals
Prior art date: 2007-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002612550A

Other languages

English (en)

Inventor

Michele Molino

Shan Chaudhuri

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

New Cell Formulations Ltd

Original Assignee

New Cell Formulations Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-21

Filing date

2007-12-21

Publication date

2008-03-11

2007-12-21 Application filed by New Cell Formulations Ltd filed Critical New Cell Formulations Ltd

2007-12-21 Priority to CA002612550A priority Critical patent/CA2612550A1/fr

2008-03-11 Publication of CA2612550A1 publication Critical patent/CA2612550A1/fr

Status Abandoned legal-status Critical Current

Links

CVSVTCORWBXHQV-UHFFFAOYSA-N anhydrous creatine Natural products NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title claims abstract description 88
229960003624 creatine Drugs 0.000 title claims abstract description 46
239000006046 creatine Substances 0.000 title claims abstract description 45
-1 Creatine pyroglutamic acid salts Chemical class 0.000 title claims abstract description 17
238000000034 method Methods 0.000 title claims abstract description 14
238000004519 manufacturing process Methods 0.000 title description 3
230000001537 neural effect Effects 0.000 claims abstract description 10
241000124008 Mammalia Species 0.000 claims abstract description 9
230000036541 health Effects 0.000 claims abstract description 7
239000000203 mixture Substances 0.000 claims description 6
230000003920 cognitive function Effects 0.000 claims description 5
230000002939 deleterious effect Effects 0.000 claims 1
230000036997 mental performance Effects 0.000 claims 1
230000036314 physical performance Effects 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 10
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 18
229940043131 pyroglutamate Drugs 0.000 description 11
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 8
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 8
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 8
MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 7
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Chemical class OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 7
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Chemical class OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
229960004826 creatine monohydrate Drugs 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229940109239 creatinine Drugs 0.000 description 5
235000015872 dietary supplement Nutrition 0.000 description 5
239000003826 tablet Substances 0.000 description 5
PBFDKFLAOSYLOL-DFWYDOINSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound NC(=N)N(C)CC([OH2+])=O.[O-]C(=O)[C@@H]1CCC(=O)N1 PBFDKFLAOSYLOL-DFWYDOINSA-N 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000030833 cell death Effects 0.000 description 4
102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 description 4
108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
229950007002 phosphocreatine Drugs 0.000 description 4
238000007363 ring formation reaction Methods 0.000 description 4
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
102100030497 Cytochrome c Human genes 0.000 description 3
108010075031 Cytochromes c Proteins 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229930195712 glutamate Natural products 0.000 description 3
229940049906 glutamate Drugs 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000002797 proteolythic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
LXYYMRRIOBTNDZ-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NC(=N)N(C)CC(O)=O.NC(=N)N(C)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O LXYYMRRIOBTNDZ-UHFFFAOYSA-N 0.000 description 2
ZRJUVYJRIFZJHD-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NC(=N)N(C)CC(O)=O.NC(=N)N(C)CC(O)=O.NC(=N)N(C)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O ZRJUVYJRIFZJHD-UHFFFAOYSA-N 0.000 description 2
208000037259 Amyloid Plaque Diseases 0.000 description 2
102000003952 Caspase 3 Human genes 0.000 description 2
108090000397 Caspase 3 Proteins 0.000 description 2
102000011727 Caspases Human genes 0.000 description 2
108010076667 Caspases Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000003929 acidic solution Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002270 ergogenic effect Effects 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229940049920 malate Drugs 0.000 description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
210000003470 mitochondria Anatomy 0.000 description 2
230000004112 neuroprotection Effects 0.000 description 2
231100000189 neurotoxic Toxicity 0.000 description 2
230000002887 neurotoxic effect Effects 0.000 description 2
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000004321 preservation Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000009469 supplementation Effects 0.000 description 2
MJGBOFOZSAEULI-RUCXOUQFSA-N (2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H]1CCC(=O)N1 MJGBOFOZSAEULI-RUCXOUQFSA-N 0.000 description 1
DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 1
MBBREGJRSROLGD-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical class NC(=N)N(C)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MBBREGJRSROLGD-UHFFFAOYSA-N 0.000 description 1
DLNGCCQFGNSBOP-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.NC(=N)N(C)CC(O)=O DLNGCCQFGNSBOP-UHFFFAOYSA-N 0.000 description 1
KLZQWPDLVGYZED-UHFFFAOYSA-N 2-aminoethanesulfonic acid;2-[carbamimidoyl(methyl)amino]acetic acid Chemical compound NCCS(O)(=O)=O.NC(=N)N(C)CC(O)=O KLZQWPDLVGYZED-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
UYCAGRPOUWSBIQ-WOYAITHZSA-N [(1s)-1-carboxy-4-(diaminomethylideneamino)butyl]azanium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H](N)CCCN=C(N)N UYCAGRPOUWSBIQ-WOYAITHZSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
150000001483 arginine derivatives Chemical class 0.000 description 1
229940075863 arginine pyroglutamate Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000002715 bioenergetic effect Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000003925 brain function Effects 0.000 description 1
201000008247 brain infarction Diseases 0.000 description 1
239000007894 caplet Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000006721 cell death pathway Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
UFIVEPVSAGBUSI-UHFFFAOYSA-N dihydroorotic acid Chemical class OC(=O)C1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-UHFFFAOYSA-N 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940117360 ethyl pyruvate Drugs 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000446 fuel Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
230000006870 function Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
235000013402 health food Nutrition 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
230000003387 muscular Effects 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
229960005010 orotic acid Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000004224 protection Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229940076788 pyruvate Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
235000014268 sports nutrition Nutrition 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229950006156 teprenone Drugs 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002612550A 2007-12-21 2007-12-21 Pyroglutamates de creatine et methodes pour leur production et leur utilisation chez des personnes Abandoned CA2612550A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002612550A CA2612550A1 (fr)	2007-12-21	2007-12-21	Pyroglutamates de creatine et methodes pour leur production et leur utilisation chez des personnes

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002612550A CA2612550A1 (fr)	2007-12-21	2007-12-21	Pyroglutamates de creatine et methodes pour leur production et leur utilisation chez des personnes

Publications (1)

Publication Number	Publication Date
CA2612550A1 true CA2612550A1 (fr)	2008-03-11

Family

ID=39182077

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002612550A Abandoned CA2612550A1 (fr)	2007-12-21	2007-12-21	Pyroglutamates de creatine et methodes pour leur production et leur utilisation chez des personnes

Country Status (1)

Country	Link
CA (1)	CA2612550A1 (fr)

2007
- 2007-12-21 CA CA002612550A patent/CA2612550A1/fr not_active Abandoned

Publication	Publication Date	Title
AU697990B2 (en)	1998-10-22	Pharmaceutical and/or dietetic compositions with antioxidant activity containing carnosine or derivatives and branched amino acids
CA2702045C (fr)	2017-07-25	Preparation orale a action rapide pouvant augmenter le taux d'arginine dans le sang contenant de la citrulline et de l'arginine
US5607969A (en)	1997-03-04	L-DOPA ethyl ester to treat Parkinson's disease
IL96699A (en)	1995-12-31	Formulations containing L-carnitine-L-tartrate
US20080064737A1 (en)	2008-03-13	Creatine pyroglutamic acid salts and methods for their production and use in individuals
US20110218244A1 (en)	2011-09-08	CREATINE ß-ALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE
ES2313616T3 (es)	2009-03-01	Utilizacion de las sales, de los compuestos de reaccion por adicion y de los compuestos complejos del acido guanidinoacetico.
US20080242727A1 (en)	2008-10-02	Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
US20080153897A1 (en)	2008-06-26	Creatine pyroglutamic acid salts and methods for their production and use in individuals
RS52129B (sr)	2012-08-31	Dijetetski dodatak koji obezbeđuje energiju skeletnim mišićima i štiti kardiovaskularni trakt
CA2674753A1 (fr)	2009-11-01	Creatine .beta.-alaninate, nouveau sel ameliorant la performance athletique
CA2612550A1 (fr)	2008-03-11	Pyroglutamates de creatine et methodes pour leur production et leur utilisation chez des personnes
WO2009079739A1 (fr)	2009-07-02	Utilisation de sel d'acide pyroglutamique de créatine pour favoriser une meilleure santé des neurones
KR20220077143A (ko)	2022-06-08	아미노산 엔티티를 포함하는 부피가 감소된 제형물
US20090005320A1 (en)	2009-01-01	Compositions comprising amino acid bicarbonate and methods of use thereof
JP2005206528A (ja)	2005-08-04	アンジオテンシン変換酵素阻害剤及び該阻害剤を含む食品
US20020002202A1 (en)	2002-01-03	Use of fumarate salt of L-carnitine or its alkanoyl derivatives in ischaemia
US7129273B2 (en)	2006-10-31	Dicreatine Malate
ITRM20000567A1 (it)	2002-05-01	Composizioni solide atte alla somministrazione orale comprendenti sali non igroscopici della l-carnitina e delle alcanoil l-carnitine con l'
HU229421B1 (en)	2013-12-30	Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q10
US7511173B2 (en)	2009-03-31	Creatine salt with enhanced nutritional and therapeutic efficacy and compositions containing same
ITRM980445A1 (it)	2000-01-03	Composizioni solide atte alla somministrazione orale comprendenti sali non igroscopici della l-carnitina e delle alcanoil l-carnitine
ITMI961116A1 (it)	1997-12-01	Sali stabili e non igroscopici di l-carnitina e di alcanoil l-carni- tine
WO2008031184A1 (fr)	2008-03-20	Sels d'acide créatine-pyroglutamique; méthodes d'obtention et d'utilisation chez un individu
CA2559374A1 (fr)	2008-03-11	Sels d'acide pyroglutamique et de creatine et methodes connexes de production et d'utilisation chez les humains

Legal Events

Date	Code	Title	Description
2007-12-21	EEER	Examination request
2010-02-19	FZDE	Dead